Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;31(5):868-871.
doi: 10.1016/j.cardfail.2025.01.030. Epub 2025 Mar 30.

Prototyping and Manufacturing of Customized Over-Encapsulated Polypills for Heart Failure With Reduced Ejection Fraction in a Safety-Net Health Care System

Affiliations

Prototyping and Manufacturing of Customized Over-Encapsulated Polypills for Heart Failure With Reduced Ejection Fraction in a Safety-Net Health Care System

Colette Dejong et al. J Card Fail. 2025 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures CD's spouse is employed by and holds stock in iRhythm Technologies. MDH (Huffman) has received travel support from the World Heart Federation and has an appointment at The George Institute for Global Health, which has a patent and license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH (Huffman) and AA plan to submit patents for heart failure with reduced ejection fraction polypills. PYH has received honoraria from Gilead, Merck and Pfizer, unrelated to this study. ATS has consulted for Lexicon Pharmaceuticals and has research funding from Novartis Pharmaceuticals and Reprieve Cardiovascular unrelated to this study.

Figures

Fig. 1.
Fig. 1.
Prototypes of customized polypills for heart failure with reduced ejection fraction. ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blocker; DOAC, direct oral anticoagulant; GDMT, guideline-directed medical therapy; HFrEF, heart failure with reduced ejection fraction; metoprolol XL, metoprolol succinate; MRA, mineralocorticoid receptor antagonist; SGLT2, sodium-glucose cotransporter-2. *Doses are listed from left to right. For generic medications, sample tablets are shown; size varies by manufacturer. **Half-tablets of sacubitril/valsartan 49/51mg and 97/103 mg were substituted for doses of 24/26 mg and 49/51 mg, respectively.

References

    1. Mastromarino V, Casenghi M, Testa M, Gabriele E, Coluccia R, Rubattu S, et al. Polypharmacy in heart failure patients. Curr Heart Fail Rep 2014;11(2):212–9. 10.1007/s11897-014-0186-8. - DOI - PubMed
    1. Agarwal A, Yancy CW, Huffman MD. Improving care for heart failure with reduced ejection fraction—a potential polypill-based strategy. JAMA 2020;324(22):2259–60. 10.1001/jama.2020.21395. - DOI - PubMed
    1. Baldridge AS, Huffman MD, Lazar D, Abbas H, Flowers FM, Quintana A, et al. Efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA): rationale and design for a randomized controlled trial. Am Heart J 2022;254:183–93. 10.1016/j.ahj.2022.09.004. - DOI - PMC - PubMed
    1. Muñoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, et al. Polypill for cardiovascular disease prevention in an underserved population. NEJM 2019;381(12):1114–23. 10.1056/NEJMoa1815359. - DOI - PMC - PubMed
    1. Chen JC, DeJong C, Agarwal M, Hairston AM, Durstenfeld MS, McKay V, et al. Stakeholder perspectives on a heart failure with reduced ejection fraction polypill: a multicenter mixed methods study. Circ: Cardiovasc Qual Outcomes 2024. Nov;17(11):e011121. - PMC - PubMed

LinkOut - more resources